The Brain Tumor Diagnostics Market size is estimated at USD 2.27 billion in 2024, and is expected to reach USD 3.36 billion by 2029, growing at a CAGR of 8.30% during the forecast period (2024-2029).
The COVID-19 pandemic had a major impact on the brain tumor diagnostics market. Diagnostic procedures were postponed at the beginning of the pandemic as the hospitals and surgeons were advised to postpone or cancel elective procedures. For instance, according to the study published by Computational and Structural Biotechnology Journal in January 2021, malignant juvenile brain tumors are known for their rapid growth, necessitating early detection and treatment. As a result, delaying diagnosis may damage its effectiveness, lowering patient survival rates. This has further impacted the growth of the brain tumor diagnostics market during the pandemic.
Moreover, Brain Tumor Research, a research organization, reported a drastic delay in the diagnosis and treatment approaches, such as chemotherapy and radiotherapy for different types of brain tumors. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for brain tumor diagnostics. Thus, COVID-19 is expected to significantly impact the brain tumor diagnostics market over the forecast period.
Factors such as the increasing prevalence of neurological disorders and cancers and the rising number of smokers are expected to drive the growth of the market over the forecast period. For instance, according to the estimates of the American Cancer Society, in 2023, about 24,810 malignant tumors of the brain or spinal cord will be diagnosed in the United States. This increase in cancer cases is expected to drive the overall brain tumor diagnostics market. Glioblastoma is an aggressive form of a brain tumor which occurs mostly in adults. It can also occur in children, but very rarely. It grows fast and spreads quickly. Quick diagnosis and treatment are necessary, as it is a fatal disorder.
Moreover, there is a rising prevalence of brain cancer across the world. For instance, according to an article published by netmed.com, in June 2022, around 330,000 children and adults globally were diagnosed with cancer of the Central Nervous System in a year. In India, central nervous system (CNS) cancer ranges from 5 to 10 per 100,000 people, with a rising trend and accounts for 2% of cancer. Thus, the increasing prevalence of brain tumors is one of the major factors augmenting the growth of the market.
Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However, high cost associated with diagnosis are projected to hamper the market growth slightly over the forecast period.
Furthermore, the increasing adoption of MRI systems is due to the establishment of new facilities in different countries worldwide. For instance, in November 2021, a sophisticated MRI facility was launched at the National Brain Research Centre (NBRC), Manesar, in Haryana, India. The National Brain Research Centre (NBRC) is India's premier institute dedicated to neuroscience research and education, and the MRI Scanner PRISMA 3T MRI from Siemens was installed at the facility.
Moreover, in February 2023, Case Western Reserve University was awarded a grant of USD 3 million to advance novel MRI and software technology for brain tumor diagnosis. This will eventually allow personalized treatment planning to improve patient outcomes.
Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.
Further, the introduction and launch of new and advanced diagnostics devices in the country by the key market players in the area are expected to augment the growth of the market in the region. For instance, in December 2021, ADM Diagnostics Inc. received FDA clearance for CorInsights MRI. CorInsights MRI provides quantitative information about brain tissue volume for radiologists, neurologists, and clinical researchers. Such launches are propelling the growth of the market in the region.
Thus, owing to the aforementioned factors, the North American brain tumor diagnostics market will likely grow significantly during the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic had a major impact on the brain tumor diagnostics market. Diagnostic procedures were postponed at the beginning of the pandemic as the hospitals and surgeons were advised to postpone or cancel elective procedures. For instance, according to the study published by Computational and Structural Biotechnology Journal in January 2021, malignant juvenile brain tumors are known for their rapid growth, necessitating early detection and treatment. As a result, delaying diagnosis may damage its effectiveness, lowering patient survival rates. This has further impacted the growth of the brain tumor diagnostics market during the pandemic.
Moreover, Brain Tumor Research, a research organization, reported a drastic delay in the diagnosis and treatment approaches, such as chemotherapy and radiotherapy for different types of brain tumors. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for brain tumor diagnostics. Thus, COVID-19 is expected to significantly impact the brain tumor diagnostics market over the forecast period.
Factors such as the increasing prevalence of neurological disorders and cancers and the rising number of smokers are expected to drive the growth of the market over the forecast period. For instance, according to the estimates of the American Cancer Society, in 2023, about 24,810 malignant tumors of the brain or spinal cord will be diagnosed in the United States. This increase in cancer cases is expected to drive the overall brain tumor diagnostics market. Glioblastoma is an aggressive form of a brain tumor which occurs mostly in adults. It can also occur in children, but very rarely. It grows fast and spreads quickly. Quick diagnosis and treatment are necessary, as it is a fatal disorder.
Moreover, there is a rising prevalence of brain cancer across the world. For instance, according to an article published by netmed.com, in June 2022, around 330,000 children and adults globally were diagnosed with cancer of the Central Nervous System in a year. In India, central nervous system (CNS) cancer ranges from 5 to 10 per 100,000 people, with a rising trend and accounts for 2% of cancer. Thus, the increasing prevalence of brain tumors is one of the major factors augmenting the growth of the market.
Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However, high cost associated with diagnosis are projected to hamper the market growth slightly over the forecast period.
Brain Tumor Diagnostics Market Trends
MRI segment is Expected to Hold a Significant Share in the Brain Tumor Diagnostics Market
Magnetic resonance imaging (MRI)is a medical imaging technique used in radiology to produce pictures of the anatomy and the body's physiological processes. These pictures are further used to diagnose and detect the presence of abnormalities in the body. Dominant share is retained by the MRI segment owing to the attributes such as high application in the diagnosis of brain tumors. The rising prevalence of brain cancer cases worldwide is expected to drive the demand for the brain tumor diagnostics market over the forecast period. For instance, according to the Canadian Cancer Society, updated in May 2022, It was estimated that in 2022, 3,200 Canadians will be diagnosed with brain and spinal cord cancer, including 1,850 men and 1,350 women.Furthermore, the increasing adoption of MRI systems is due to the establishment of new facilities in different countries worldwide. For instance, in November 2021, a sophisticated MRI facility was launched at the National Brain Research Centre (NBRC), Manesar, in Haryana, India. The National Brain Research Centre (NBRC) is India's premier institute dedicated to neuroscience research and education, and the MRI Scanner PRISMA 3T MRI from Siemens was installed at the facility.
Moreover, in February 2023, Case Western Reserve University was awarded a grant of USD 3 million to advance novel MRI and software technology for brain tumor diagnosis. This will eventually allow personalized treatment planning to improve patient outcomes.
Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.
North America is Anticipated to Register a Significant Growth in Brain Tumor Diagnostics Market
The North American brain tumor diagnostics market is projected to have a significant share over the forecast period. The United States is anticipated to lead the market. This is attributed to the developed healthcare industry, coupled with rising awareness regarding advanced technologies among the population in this region. For instance, according to the American Brain Tumor Association, more than 84,000 people were diagnosed with a primary brain tumor in 2021, and approximately 18,000 people died in 2021 as a result of a primary malignant brain tumor. In addition, according to the same source, more than 28,000 children in the United States will be diagnosed with a brain tumor in 2021. The rising prevalence of brain tumors is expected to drive the growth of this region.Further, the introduction and launch of new and advanced diagnostics devices in the country by the key market players in the area are expected to augment the growth of the market in the region. For instance, in December 2021, ADM Diagnostics Inc. received FDA clearance for CorInsights MRI. CorInsights MRI provides quantitative information about brain tissue volume for radiologists, neurologists, and clinical researchers. Such launches are propelling the growth of the market in the region.
Thus, owing to the aforementioned factors, the North American brain tumor diagnostics market will likely grow significantly during the forecast period.
Brain Tumor Diagnostics Industry Overview
The brain tumor diagnostics market is consolidated in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known,, including GE Healthcare, Koninklijke Philips N.V., Siemens Healthcare GmbH, Fujifilm Corporation, and Hitachi, Ltd, among others.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GE Healthcare
- Koninklijke Philips N.V.
- Siemens Healthcare GmbH
- Fujifilm Corporation
- Hitachi, Ltd.
- Hologic, Inc.
- NantOmics
- Thermo Fisher Scientific
Methodology
LOADING...
